테고사이언스
Financials
Valuation Metrics
테고사이언스's Market Cap is ₩530B. At end of 2025 it was ₩1322B. Ranked #1730 of 2,436 in KR market (top 71%), #1042 of 1,649 on KOSDAQ (top 63%), #189 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 81%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 52.95B KRW | KR#1,730/2,436 Sec#189/234 |
| Revenue | 5.83B KRW | KR#2,336/2,436 Sec#191/234 |
| Net Income | -8.37B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 75.05B KRW | KR#1,941/2,436 Sec#162/234 |
| Net Assets | 48.32B KRW | KR#1,897/2,436 Sec#163/234 |
| Employees | 39 | KR#2,116/2,436 Sec#194/234 |
| Value | ||
| P/B | 1.10x | KR#1,545/2,436 Sec#102/234 |
| P/S | 9.09x | KR#2,258/2,436 Sec#159/234 |
| FCF Yield | -5.89% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -17.33% | KR#2,029/2,436 Sec#160/234 |
| ROA | -11.16% | KR#2,107/2,436 Sec#166/234 |
| Op. Margin | -92.73% | KR#2,305/2,436 Sec#173/234 |
| Revenue Growth | -8.69% | KR#1,830/2,436 Sec#169/234 |
| Financial Health | ||
| Debt Ratio | 155.33% | KR#1,261/2,436 Sec#143/234 |
| Total Debt | 1.25B KRW | KR#1,938/2,436 Sec#188/234 |
| FCF | -3.12B KRW | KR#1,400/2,436 Sec#108/234 |
| Cash | 9.60B KRW | KR#1,693/2,436 Sec#136/234 |
| Current Ratio | 25.95x | KR#20/2,436 Sec#8/234 |
| Performance | ||
| 1Y Return | -61.01% | KR#2,259/2,436 Sec#214/234 |
| 1M Return | -11.04% | KR#1,921/2,436 Sec#179/234 |
| From 52W High | -66.29% | KR#2,023/2,436 Sec#172/234 |
| 1Y MDD | -70.48% | KR#1,972/2,436 Sec#173/234 |
| Trading | ||
| Volume | 2,819 shares | KR#2,338/2,436 Sec#229/234 |
| Foreign Own. | 1.52% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -1,031 KRW | KR—/2,436 Sec—/234 |
| BPS | 6,058 KRW | KR#1,295/2,436 Sec#91/234 |
Company Info
Tegosciece, established in 2001 and listed on KOSDAQ in 2014, specializes in the development, manufacturing, and sale of cell therapy products. Utilizing world-class cell culture technology, the company is a leader, holding three of 16 approved cell therapy products (Holoderm, Caloderm, Rosmir). Initially developing wound healing cell therapy products for burns and foot ulcers, Tegosciece is now expanding into regenerative medicine new drug development for musculoskeletal diseases, including domestic and U.S. clinical trials for rotator cuff tear treatment. It is headquartered in Gangseo-gu, Seoul.